Literature DB >> 28890238

Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint.

Yasmin Granot1, Dan Peer2.   

Abstract

mRNA molecules hold tremendous potential as a tool for gene therapy of a wide range of diseases. However, the main hurdle in implementation of mRNA for therapeutics, the systemic delivery of mRNA molecules to target cells, remains a challenge. A feasible solution for this challenge relies in the rapidly evolving field of nucleic acid-loaded nanocarriers and specifically in the established family of lipid-based nanoparticles (LNPs). Herein, we will discuss the main factors, which determine the fate of modified mRNA (mmRNA)-loaded LNPs in-vivo, and will focus on their interactions with the innate immune system as a main consideration in the design of lipid-based mmRNA delivery platforms.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Lipid nanoparticles; Mononuclear phagocytic system; Pattern recognition receptors; RNA modifications; Systemic delivery; mRNA

Mesh:

Substances:

Year:  2017        PMID: 28890238     DOI: 10.1016/j.smim.2017.08.015

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  33 in total

Review 1.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.

Authors:  Piotr S Kowalski; Arnab Rudra; Lei Miao; Daniel G Anderson
Journal:  Mol Ther       Date:  2019-02-19       Impact factor: 11.454

Review 2.  RNA delivery biomaterials for the treatment of genetic and rare diseases.

Authors:  Weiyu Zhao; Xucheng Hou; Olivia G Vick; Yizhou Dong
Journal:  Biomaterials       Date:  2019-06-20       Impact factor: 12.479

3.  Ionizable Lipid Nanoparticle-Mediated Delivery of Plasmid DNA in Cardiomyocytes.

Authors:  Sérgio Scalzo; Anderson K Santos; Heloísa A S Ferreira; Pedro A Costa; Pedro H D M Prazeres; Natália J A da Silva; Lays C Guimarães; Mário de Morais E Silva; Marco T R Rodrigues Alves; Celso T R Viana; Itamar C G Jesus; Alice P Rodrigues; Alexander Birbrair; Anderson O Lobo; Frederic Frezard; Michael J Mitchell; Silvia Guatimosim; Pedro Pires Goulart Guimaraes
Journal:  Int J Nanomedicine       Date:  2022-06-30

Review 4.  Nanoscale platforms for messenger RNA delivery.

Authors:  Bin Li; Xinfu Zhang; Yizhou Dong
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-05-04

Review 5.  Biomaterials as Tools to Decode Immunity.

Authors:  Haleigh B Eppler; Christopher M Jewell
Journal:  Adv Mater       Date:  2019-11-29       Impact factor: 30.849

6.  Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.

Authors:  Margaret M Billingsley; Nathan Singh; Pranali Ravikumar; Rui Zhang; Carl H June; Michael J Mitchell
Journal:  Nano Lett       Date:  2020-02-05       Impact factor: 11.189

7.  Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening.

Authors:  Pedro P G Guimaraes; Rui Zhang; Roman Spektor; Mingchee Tan; Amanda Chung; Margaret M Billingsley; Rakan El-Mayta; Rachel S Riley; Lili Wang; James M Wilson; Michael J Mitchell
Journal:  J Control Release       Date:  2019-10-31       Impact factor: 9.776

8.  Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver.

Authors:  Rui Zhang; Rakan El-Mayta; Timothy J Murdoch; Claude C Warzecha; Margaret M Billingsley; Sarah J Shepherd; Ningqiang Gong; Lili Wang; James M Wilson; Daeyeon Lee; Michael J Mitchell
Journal:  Biomater Sci       Date:  2021-01-06       Impact factor: 6.843

Review 9.  Delivery technologies to engineer natural killer cells for cancer immunotherapy.

Authors:  Rakan El-Mayta; Zijing Zhang; Alex G Hamilton; Michael J Mitchell
Journal:  Cancer Gene Ther       Date:  2021-04-22       Impact factor: 5.854

10.  Lipid- and Polymer-Based Nanoparticle Systems for the Delivery of CRISPR/Cas9.

Authors:  Bhaargavi Ashok; Nicholas A Peppas; Marissa E Wechsler
Journal:  J Drug Deliv Sci Technol       Date:  2021-07-11       Impact factor: 5.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.